Ignite Creation Date:
2025-12-25 @ 4:10 AM
Ignite Modification Date:
2025-12-26 @ 3:07 AM
Study NCT ID:
NCT07064720
Status:
RECRUITING
Last Update Posted:
2025-07-15
First Post:
2025-07-06
Is NOT Gene Therapy:
False
Has Adverse Events:
False
Brief Title:
Adding Dexmedetomidine to Mannitol to Attenuate the Increase of Intracranial Pressure
Sponsor:
Cairo University
Organization:
Study Overview
Official Title:
Adding Dexmedetomidine to Mannitol to Attenuate the Increase of Intracranial Pressure
Status:
RECRUITING
Status Verified Date:
2024-07
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Dexmedetomidine is a potent alpha-2 adrenergic receptor agonist. In addition, dexmedetomidine-induced stimulation of the postsynaptic alpha-2 adrenergic receptor on the cerebral blood vessels can cause cerebral vasoconstriction and decrease cerebral blood flow
Detailed Description:
None
Study Oversight
Has Oversight DMC:
True
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
False
Is an FDA AA801 Violation?: